Brief: Baudax Bio Announces Publication Of Phase Iiib Data On Preoperative Administration Of Anjeso® In Patients Undergoing Total Knee Arthroplasty (Tka) In Pain Medicine
26/04/2021 14:12
April 26 (Reuters) - Baudax Bio Inc BXRX.O :
* BAUDAX BIO ANNOUNCES PUBLICATION OF PHASE IIIB DATA ON
PREOPERATIVE ADMINISTRATION OF ANJESO® IN PATIENTS UNDERGOING
TOTAL KNEE ARTHROPLASTY (TKA) IN PAIN MEDICINE
* BAUDAX BIO INC - ANJESO TREATED TKA PATIENTS DEMONSTRATED
DECREASED OPIOID CONSUMPTION FOLLOWING SURGERY
* BAUDAX BIO INC - TOTAL MEAN HOSPITAL CHARGES FOR HOSPITAL
STAY
AND TOTAL OVERALL CHARGES WERE LOWER IN ANJESO GROUP COMPARED TO
PLACEBO
Source text for Eikon: ID:nGNX2qpp88
Further company coverage: BXRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Baudax Bio
See all newsBrief: Baudax Bio On Feb 22, Filed Voluntary Petition Under Chapter 11 Of U.S. Bankruptcy Code
Brief: Baudax Bio Says Substantial Doubt Exists About Ability To Continue As A Going Concern For Next Twelve Months
Baudax Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Baudax Bio Says Phase 1/2a Clinical Study of TI-168 In Hemophilia A with FVIII Inhibitors Projected to Begin Q1 2024
Brief: Baudax Bio Inc - On October 5, 2023, Board Of Directors Of Company Appointed Natalie Mcandrew As Interim Chief Financial Officer